8-K: ALX Oncology Faces Nasdaq Delisting Notice Due to Minimum Bid Price Deficiency

ALX Oncology Holdings Inc. received a notice from Nasdaq on April 23, 2025, indicating non-compliance with the minimum bid price requirement for continued listing.

Summary

• ALX Oncology Holdings Inc. received a notification from Nasdaq on April 23, 2025, stating that it doesn't meet the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
• The company has 180 calendar days, until October 20, 2025, to regain compliance.
• To regain compliance, the company's stock price must be at least $1.00 per share for a minimum of ten consecutive business days.
• If compliance isn't achieved within the initial 180 days, the company may be eligible for a second 180-day compliance period by transferring to the Nasdaq Capital Market, provided it meets other listing requirements.
• Failure to regain compliance within the allotted time may result in delisting of the company's stock.
• The company intends to monitor its stock price and consider actions like a reverse stock split to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice, indicating potential financial distress and uncertainty about the company's future.

Negatives

• ALX Oncology is not in compliance with Nasdaq's minimum bid price requirement.
• The company faces potential delisting if it fails to regain compliance by October 20, 2025.

Risks

• There is no guarantee that ALX Oncology will regain compliance with the minimum bid price requirement.
• The company's stock may be delisted from the Nasdaq Global Select Market if compliance is not achieved.
• The company may not be eligible for a second compliance period or receive an extension from Nasdaq.
• A reverse stock split may negatively impact shareholders.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock and assess potential actions to regain compliance during the 180-calendar day compliance period, including effecting a reverse stock split, if necessary.

Industry Context

Delisting notices are not uncommon for biotech companies facing financial or clinical trial setbacks, reflecting the high-risk nature of the industry.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining Nasdaq listing requirements.
• A reverse stock split is a common strategy employed by companies in this situation, although it can be viewed negatively by investors.
• Companies like Geron Corporation have faced similar delisting warnings and have implemented reverse stock splits to regain compliance.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty about their job security.
• The company's ability to raise capital may be impaired.

Next Steps

• ALX Oncology will monitor its stock price.
• ALX Oncology will assess potential actions to regain compliance, including a reverse stock split.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, compliance, ALX Oncology, ALXO, stock price, reverse stock split